29 Dec 2020 07:01
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Update re AbC-19TM Rapid Test
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes today's update from Abingdon Health plc (AIM: ABDX) regarding the AbC-19TM Rapid Test and welcomes confirmation that they continue to work constructively with the Medicines and Healthcare products Regulatory Agency (MHRA) to try to enable approval for home use and self-test of the AbC-19TM Rapid Test in the UK.
Abingdon have also confirmed that whilst the DHSC continues to have first refusal for supplies of the AbC-19TM Rapid Test through a Supply of Goods Contract that extends to 14 February 2021, the UK-RTC is liaising with customers and regulatory authorities across a total of 27 international territories, to allow future use of the product outside of the UK.
Colin King, CEO of Omega Diagnostics, said: "We welcome the update from Abingdon Health this morning and we look forward to being able to update investors on this approval process for self-test use in due course. We remain confident that the AbC-19TM Rapid Test has a potential global application and we are delighted that the UK-RTC maintains constructive dialogue with interested customers and regulatory authorities across the world."
Contacts:
Omega Diagnostics Group PLC | Tel: 01259 763 030 |
Bill Rhodes, Interim Non-Executive Chairman Colin King, Chief Executive | www.omegadiagnostics.com |
Kieron Harbinson, Group Finance Director | |
finnCap Ltd | Tel: 020 7220 0500 |
Geoff Nash/Edward Whiley (Corporate Finance) | |
Alice Lane (ECM) | |
Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |